| Entry |
|
|---|
| Name |
Zolmitriptan (JAN/USP/INN);
Zomig (TN) |
|---|
| Product |
|
|---|
| Generic |
ZOLMIPTRIPTAN (Glenmark Pharmaceuticals), ZOLMITRIPTAN (Ajanta Pharma USA), ZOLMITRIPTAN (Alembic Pharmaceuticals Limited), ZOLMITRIPTAN (Alembic Pharmaceuticals Limited), ZOLMITRIPTAN (Alembic Pharmaceuticals), ZOLMITRIPTAN (Alembic Pharmaceuticals), ZOLMITRIPTAN (Amneal Pharmaceuticals), ZOLMITRIPTAN (Aurobindo Pharma Limited), ZOLMITRIPTAN (BluePoint Laboratories), ZOLMITRIPTAN (Bryant Ranch Prepack), ZOLMITRIPTAN (CELLTRION USA), ZOLMITRIPTAN (Cipla USA), ZOLMITRIPTAN (Direct_Rx), ZOLMITRIPTAN (Direct_Rx), ZOLMITRIPTAN (Glenmark Pharmaceuticals), ZOLMITRIPTAN (Medstone Pharma LLC), ZOLMITRIPTAN (PLD Acquisitions LLC DBA Avéma Pharma Solutions), ZOLMITRIPTAN (Padagis Israel Pharmaceuticals), ZOLMITRIPTAN (Quality Care Products), ZOLMITRIPTAN (Rising Pharma Holdings), ZOLMITRIPTAN (Zydus Lifesciences Limited), ZOLMITRIPTAN (Zydus Lifesciences Limited), ZOLMITRIPTAN (Zydus Pharmaceuticals USA), ZOLMITRIPTAN (Zydus Pharmaceuticals USA), ZOMIG (Amneal Pharmaceuticals LLC) |
|---|
| Formula |
C16H21N3O2
|
|---|
| Exact mass |
287.1634
|
|---|
| Mol weight |
287.3568
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 2160 |
|
|---|
| Efficacy |
Antimigraine, Vasoconstrictor, Serotonin receptor agonist |
|---|
| Comment |
Sumatriptan derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
Enzyme: CYP1A2 [HSA: 1544], MAOA [HSA: 4128]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07211 | Serotonin receptor agonists/antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N02 ANALGESICS
N02C ANTIMIGRAINE PREPARATIONS
N02CC Selective serotonin (5HT1) agonists
N02CC03 Zolmitriptan
D00415 Zolmitriptan (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antimigraine Agents
Serotonin (5-HT) Receptor Agonists
Zolmitriptan
D00415 Zolmitriptan (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
216 Vasoconstrictors
2160 Vasoconstrictors
D00415 Zolmitriptan (JAN/USP/INN)
Drug groups [BR:br08330]
Analgesic
DG01484 5-HT1B-receptor agonist
D00415 Zolmitriptan
DG01485 5-HT1D-receptor agonist
D00415 Zolmitriptan
DG01518 5-HT1B/1D-receptor agonist
D00415 Zolmitriptan
DG01943 Triptan
D00415 Zolmitriptan
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
D00415 Zolmitriptan
DG02917 MAO substrate
DG03178 MAOA substrate
D00415 Zolmitriptan
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Serotonin
HTR1B
D00415 Zolmitriptan (JAN/USP/INN) <JP/US>
HTR1D
D00415 Zolmitriptan (JAN/USP/INN) <JP/US>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D00415
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00415
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 21
1 C8y C 24.7800 -23.1700
2 C8y C 24.7800 -24.5700
3 C8y C 26.1800 -22.7500
4 C8x C 23.5900 -22.4700
5 N4x N 26.1800 -25.0600
6 C8x C 23.5900 -25.2700
7 C8x C 26.9500 -23.8700
8 C1b C 26.6000 -21.4900
9 C8y C 22.4000 -23.1700
10 C8x C 22.4000 -24.6400
11 C1b C 28.0000 -21.2100
12 C1b C 21.1400 -22.4000
13 N1c N 28.4200 -19.8800
14 C1y C 19.9500 -23.1700
15 C1a C 27.5800 -18.8300
16 C1a C 29.8200 -19.6000
17 N1x N 19.9500 -24.5000
18 C1x C 18.6200 -22.6800
19 C7x C 18.5500 -24.9200
20 O7x O 17.7800 -23.8000
21 O6a O 18.0600 -26.2500
BOND 23
1 1 2 2
2 1 3 1
3 1 4 1
4 2 5 1
5 2 6 1
6 3 7 2
7 3 8 1
8 4 9 2
9 6 10 2
10 8 11 1
11 9 12 1
12 11 13 1
13 14 12 1 #Down
14 13 15 1
15 13 16 1
16 14 17 1
17 14 18 1
18 17 19 1
19 18 20 1
20 19 21 2
21 5 7 1
22 9 10 1
23 19 20 1
|
|---|
